AI Science Tracker
EN

Department of Urology, Tianjin Medical University General Hospital, Tianjin, China

1 discovery from 2023

Discoveries

Machine learning prioritizes candidate diabetic nephropathy diagnostic markers

Source check: Source checked. Not independent scientific confirmation.

Finding: WGCNA and machine-learning analyses of expression datasets prioritized three candidate diabetic-nephropathy markers, with external expression data and single-nucleus data used for preliminary checks. The cohorts are small and retrospective; the authors note that more experiments are needed before clinical use.

Technology: WGCNA and multiple machine-learning methods prioritized candidate diagnostic markers from expression datasets.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
WGCNA and machine-learning methods prioritized candidate diagnostic markers from expression datasets.
Test and result
The study reports three candidate markers and external expression/ROC assessment in a small dataset, with expression localization checked in single-nucleus data.
Limitation / still unknown
Small retrospective datasets do not establish diagnostic performance or clinical utility.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1084531/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary full-text review as recorded in case evidence; record-level claim and attribution review..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.